Skip to search formSkip to main contentSkip to account menu

DT(388)IL3 fusion protein

Known as: IL3R-targeting Fusion Protein SL-401, SL-401, DT(388)-IL3 Fusion Protein 
A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
7058 Background: Patients with myelofibrosis (MF) who fail or are intolerant to JAK inhibitors (JAKi) have no standard treatment… 
Review
2019
Review
2019
NP BPDCN is an aggressive cancer of the blood and bone marrow that presents clinically as a hybrid of lymphoma and leukemia. In… 
2016
2016
7006Background: SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), a target overexpressed on BPDCN and… 
2016
2016
Background: The bone marrow microenvironment of many multiple myeloma (MM) patients harbors high quantities of plasmacytoid… 
2015
2015
Background: SL-401 is a novel biologic delivering a truncated diphtheria toxin, a highly potent protein synthesis inhibitor, to… 
2013
2013
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematologic malignancy derived from plasmacytoid dendritic… 
2012
2012
Abstract 3625 Background: SL-401 is a novel biologic targeted therapy, comprised of human IL-3 coupled to a truncated diphtheria… 
2010
2010
Abstract 3298 Background and Rationale: SL-401 (DT388IL3) is a novel cancer stem cell (CSC)-directed recombinant biologic agent…